Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile.

ABSTRACT:

Background

Although accumulated evidence provides a strong scientific premise for using immune profiles to predict survival in patients with cancer, a universal immune profile across tumor types is still lacking, and how to achieve a survival-associated immune profile remains to be evaluated.

Methods

We analyzed datasets from The Cancer Genome Atlas to identify an immune profile associated with prolonged overall survival in multiple tumor types and tested the efficacy of tumor cell-surface vimentin-targeted interleukin 12 (ttIL-12) in inducing that immune profile and prolonging survival in both mouse and patient-derived xenograft tumor models.

Results

We identified an immune profile (IFNγ^HiCD8^HiFOXP3^LowCD33^Low) associated wi

SUBMITTER: Zhao Q 

PROVIDER: S-EPMC6580640 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature